EMA Recommends Dapivirine Vaginal Ring for HIV Prevention in Teens

The European Medicines Agency (EMA) has formally recommended an extension of indication for the dapivirine vaginal ring to include its use in women aged 16 and older. This decision, announced by the Committee for Medicinal Products for Human Use (CHMP) on June 20, 2025, aims to enhance public health measures against HIV-1 infection, particularly among younger women who are at significant risk.

The dapivirine ring, a revolutionary long-acting HIV prevention technology, was initially approved in July 2020 for women aged 18 and older, providing a crucial alternative for those unable to use oral pre-exposure prophylaxis (PrEP). The vaginal ring, crafted from flexible silicone, releases the antiretroviral drug dapivirine over a 28-day period, effectively preventing the virus from replicating within healthy cells.

In its latest assessment, the EMA emphasized the importance of addressing prior uncertainties regarding the risk of resistance to the drug and the benefits for younger women. Following extensive studies, including a significant clinical trial involving nearly 2,000 women in sub-Saharan Africa, it was determined that the dapivirine ring can reduce the risk of HIV infection by over one-third compared to a placebo. The ring is intended for women who may not be using other forms of HIV prevention.

The EMA's endorsement is particularly significant as it expands the options available for HIV prevention, broadening the choices beyond traditional condoms and oral PrEP. This initiative aligns with global health strategies aimed at combating the HIV epidemic, especially in low- and middle-income countries where access to preventive health measures is critical.

Dr. Maria Gonzalez, a public health expert from the World Health Organization (WHO), stated, "The extension of approval for the dapivirine ring to younger women is a milestone in addressing the HIV epidemic among vulnerable populations. It aligns with our mission to enhance access to essential medicines worldwide."

The dapivirine ring was developed by the International Partnership for Microbicides and later acquired by the Population Council in 2022. Following its initial approval in Zimbabwe, the ring has received subsequent approvals in several other African nations, highlighting its efficacy and acceptance in diverse healthcare settings.

In summary, the EMA's recommendation represents a pivotal advancement in HIV prevention strategies, particularly for teenagers, and underscores the ongoing commitment to public health initiatives that protect vulnerable populations. As global health organizations continue to advocate for comprehensive prevention strategies, the dapivirine vaginal ring stands out as a promising tool in the fight against HIV.